3 documents found, page 1 of 1
Cerebral venous thrombosis due to vaccine-induced immune thrombotic thrombocyto...
Krzywicka, Katarzyna; van de Munckhof, Anita; Zimmermann, Julian; Bode, Felix J.; Frisullo, Giovanni; Karapanayiotides, Theodoros; Pötzsch, BerndCerebral venous thrombosis (CVT) is the most common and severe manifestation of vaccine-induced immune thrombotic thrombocytopenia (VITT), which is a rare side effect of the SARS-CoV-2 vaccine ChAdOx1 nCoV-19 (Vaxzevria, AstraZeneca/Oxford). The absolute risk of VITT and VITT-related CVT is estimated at 20 and 8 per million first doses of ChAdOx1 nCoV-19, respectively. So far, no definite VITT cases occurring a...
Management of cerebral venous thrombosis due to adenoviral COVID-19 vaccination
Scutelnic, Adrian; Krzywicka, Katarzyna; Mbroh, Joshua; van de Munckhof, Anita; van Kammen, Mayte Sánchez; de Sousa, Diana Aguiar; Lindgren, ErikObjective: Cerebral venous thrombosis (CVT) caused by vaccine-induced immune thrombotic thrombocytopenia (VITT) is a rare adverse effect of adenovirus-based severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2) vaccines. In March 2021, after autoimmune pathogenesis of VITT was discovered, treatment recommendations were developed. These comprised immunomodulation, non-heparin anticoagulants, and avoidance...
Global impact of COVID-19 on stroke care and IV thrombolysis
Nogueira, Raul G.; Qureshi, Muhammad M.; Abdalkader, Mohamad; Martins, Sheila Ouriques; Yamagami, Hiroshi; Qiu, Zhongming; Mansour, Ossama YassinObjective: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March 1 to June 30, 2020) compared with 2 control 4-month periods. Methods: We conducted a cross-sectional, observational, retrospective study across 6 continents, 70 countries, and 457 stroke centers. Diagnoses were identified ...